{
    "nctId": "NCT00094861",
    "title": "A Phase 2 Study to Evaluate the Efficacy and Safety of Palifermin (Recombinant Human Keratinocyte Growth Factor) in the Reduction of Dysphagia in Patients Receiving Concurrent Chemoradiotherapy Followed by Consolidation Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "symPyJSON": {
        "type": "and",
        "operands": [
            {
                "type": "and",
                "operands": [
                    {
                        "type": "variable",
                        "value": "Patients with a histologically or cytologically proven diagnosis of NSCLC"
                    },
                    {
                        "type": "variable",
                        "value": "Unresectable (locally advanced) stage IIIa or IIIb disease"
                    },
                    {
                        "type": "variable",
                        "value": "Initial radiotherapy field of treatment to encompass greater than or equal to 30% of the esophagus"
                    },
                    {
                        "type": "variable",
                        "value": "Life expectancy greater than or equal to 6 months"
                    },
                    {
                        "type": "variable",
                        "value": "Estimated weight loss less than or equal to 10% in the 3 months before study randomization"
                    },
                    {
                        "type": "variable",
                        "value": "Measurable disease"
                    },
                    {
                        "type": "variable",
                        "value": "18 years of age or older"
                    },
                    {
                        "type": "variable",
                        "value": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2"
                    },
                    {
                        "type": "variable",
                        "value": "Hemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization"
                    },
                    {
                        "type": "variable",
                        "value": "Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L without growth factor use in the 2 weeks before study randomization"
                    },
                    {
                        "type": "variable",
                        "value": "Platelet count greater than or equal to 100 x 10^9/L"
                    },
                    {
                        "type": "variable",
                        "value": "Serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN)"
                    },
                    {
                        "type": "variable",
                        "value": "Serum creatinine less than or equal to 2.0 mg/dL"
                    },
                    {
                        "type": "variable",
                        "value": "Females of childbearing potential: negative serum or urine pregnancy test"
                    },
                    {
                        "type": "variable",
                        "value": "Patient must give written informed consent before participating in any study-specific procedure, randomization, or receiving investigational product."
                    },
                    {
                        "type": "variable",
                        "value": "Patients with reproductive capability must agree to practice adequate contraception methods."
                    },
                    {
                        "type": "variable",
                        "value": "Must have minimum age of 18 Years"
                    }
                ]
            },
            {
                "type": "not",
                "operands": [
                    {
                        "type": "or",
                        "operands": [
                            {
                                "type": "variable",
                                "value": "Metastatic disease (M1)/stage 4 NSCLC"
                            },
                            {
                                "type": "variable",
                                "value": "Pleural or pericardial effusion greater than 100 ml in volume as documented by appropriate imaging"
                            },
                            {
                                "type": "variable",
                                "value": "Plan to remove the tumor surgically before completing the protocol chemo/radiotherapy course"
                            },
                            {
                                "type": "variable",
                                "value": "Shielding of any part of the esophagus during radiotherapy (including posterior spinal cord shielding)"
                            },
                            {
                                "type": "variable",
                                "value": "Prior chemotherapy, radiotherapy, or surgery for NSCLC"
                            },
                            {
                                "type": "variable",
                                "value": "Prior invasive malignancy during the past 3 years other than non-melanomatous skin cancer"
                            },
                            {
                                "type": "variable",
                                "value": "Presence or history of dysphagia or conditions predisposing to dysphagia"
                            },
                            {
                                "type": "variable",
                                "value": "History of pancreatitis"
                            },
                            {
                                "type": "variable",
                                "value": "Four weeks or less since completion of treatment using an investigational product/device in another clinical study or presence of any unresolved toxicity from previous treatment"
                            },
                            {
                                "type": "variable",
                                "value": "Previous treatment on this study or with a fibroblast growth factor"
                            },
                            {
                                "type": "variable",
                                "value": "Known to be sero-positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)"
                            },
                            {
                                "type": "variable",
                                "value": "Pregnant or breastfeeding women"
                            },
                            {
                                "type": "variable",
                                "value": "Known sensitivity to E. coli derived products"
                            },
                            {
                                "type": "variable",
                                "value": "Compromised ability of the patient to give written informed consent and/or to comply with study procedures"
                            },
                            {
                                "type": "variable",
                                "value": "Refusal to sign an informed consent form to participate in this study, and sign the hospital information release form, if applicable"
                            },
                            {
                                "type": "variable",
                                "value": "Unwilling or unable to complete the patient reported outcome (PRO) questionnaires"
                            },
                            {
                                "type": "variable",
                                "value": "Psychological, social, familial, or geographical reasons that would prevent regular follow-up"
                            }
                        ]
                    }
                ]
            }
        ]
    },
    "symPyExpression": "And(Symbol('18 years of age or older'), Symbol('Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L without growth factor use in the 2 weeks before study randomization'), Symbol('Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2'), Symbol('Estimated weight loss less than or equal to 10% in the 3 months before study randomization'), Symbol('Females of childbearing potential: negative serum or urine pregnancy test'), Symbol('Hemoglobin (hgb) greater than or equal to 10 g/dL without transfusional support or growth factor use in the 4 weeks before study randomization'), Symbol('Initial radiotherapy field of treatment to encompass greater than or equal to 30% of the esophagus'), Symbol('Life expectancy greater than or equal to 6 months'), Symbol('Measurable disease'), Symbol('Must have minimum age of 18 Years'), Symbol('Patient must give written informed consent before participating in any study-specific procedure, randomization, or receiving investigational product.'), Symbol('Patients with a histologically or cytologically proven diagnosis of NSCLC'), Symbol('Patients with reproductive capability must agree to practice adequate contraception methods.'), Symbol('Platelet count greater than or equal to 100 x 10^9/L'), Symbol('Serum bilirubin less than or equal to 1.5 x institutional upper limit of normal (ULN)'), Symbol('Serum creatinine less than or equal to 2.0 mg/dL'), Symbol('Unresectable (locally advanced) stage IIIa or IIIb disease'), Not(Or(Symbol('Compromised ability of the patient to give written informed consent and/or to comply with study procedures'), Symbol('Four weeks or less since completion of treatment using an investigational product/device in another clinical study or presence of any unresolved toxicity from previous treatment'), Symbol('History of pancreatitis'), Symbol('Known sensitivity to E. coli derived products'), Symbol('Known to be sero-positive for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV)'), Symbol('Metastatic disease (M1)/stage 4 NSCLC'), Symbol('Plan to remove the tumor surgically before completing the protocol chemo/radiotherapy course'), Symbol('Pleural or pericardial effusion greater than 100 ml in volume as documented by appropriate imaging'), Symbol('Pregnant or breastfeeding women'), Symbol('Presence or history of dysphagia or conditions predisposing to dysphagia'), Symbol('Previous treatment on this study or with a fibroblast growth factor'), Symbol('Prior chemotherapy, radiotherapy, or surgery for NSCLC'), Symbol('Prior invasive malignancy during the past 3 years other than non-melanomatous skin cancer'), Symbol('Psychological, social, familial, or geographical reasons that would prevent regular follow-up'), Symbol('Refusal to sign an informed consent form to participate in this study, and sign the hospital information release form, if applicable'), Symbol('Shielding of any part of the esophagus during radiotherapy (including posterior spinal cord shielding)'), Symbol('Unwilling or unable to complete the patient reported outcome (PRO) questionnaires'))))"
}